Literature DB >> 33452178

NTPDase8 protects mice from intestinal inflammation by limiting P2Y6 receptor activation: identification of a new pathway of inflammation for the potential treatment of IBD.

Mabrouka Salem1,2, Joanna Lecka2, Julie Pelletier2, Danielle Gomes Marconato1,2, Aline Dumas3, Luc Vallières3,4, Gaetan Brochu5,6, Bernard Robaye7, Christian Jobin8, Jean Sévigny9,2.   

Abstract

OBJECTIVE: Nucleotides are danger signals that activate inflammatory responses via binding P2 receptors. The nucleoside triphosphate diphosphohydrolase-8 (NTPDase8) is an ectonucleotidase that hydrolyses P2 receptor ligands. We investigated the role of NTPDase8 in intestinal inflammation.
DESIGN: We generated NTPDase8-deficient (Entpd8 -/-) mice to define the role of NTPDase8 in the dextran sodium sulfate (DSS) colitis model. To assess inflammation, colons were collected and analysed by histopathology, reverse transcriptase-quantitative real-time PCR (RT-qPCR) and immunohistochemistry. P2 receptor expression was analysed by RT-qPCR on primary intestinal epithelium and NTPDase8 activity by histochemistry. The role of intestinal P2Y6 receptors was assessed by bone marrow transplantation experiments and with a P2Y6 receptor antagonist.
RESULTS: NTPDase8 is the dominant enzyme responsible for the hydrolysis of nucleotides in the lumen of the colon. Compared with wild-type (WT) control mice, the colon of Entpd8 -/- mice treated with DSS displayed significantly more histological damage, immune cell infiltration, apoptosis and increased expression of several proinflammatory cytokines. P2Y6 was the dominant P2Y receptor expressed at the mRNA level by the colonic epithelia. Irradiated P2ry6 -/- mice transplanted with WT bone marrow were fully protected from DSS-induced intestinal inflammation. In agreement, the daily intrarectal injection of a P2Y6 antagonist protected mice from DSS-induced intestinal inflammation in a dose-dependent manner. Finally, human intestinal epithelial cells express NTPDase8 and P2Y6 similarly as in mice.
CONCLUSION: NTPDase8 protects the intestine from inflammation most probably by limiting the activation of P2Y6 receptors in colonic epithelial cells. This may provide a novel therapeutic strategy for the treatment of inflammatory bowel disease. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  gastrointestinal immune response; inflammatory bowel disease; intestinal epithelium

Mesh:

Substances:

Year:  2021        PMID: 33452178     DOI: 10.1136/gutjnl-2020-320937

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  5 in total

Review 1.  Exploration of the link between gut microbiota and purinergic signalling.

Authors:  MingJian Li; BoWen Liu; Rong Li; Ping Yang; Ping Leng; Yong Huang
Journal:  Purinergic Signal       Date:  2022-09-19       Impact factor: 3.950

2.  Synthesis and pharmacological characterization of multiply substituted 2H-chromene derivatives as P2Y6 receptor antagonists.

Authors:  Young-Hwan Jung; Qasim Shah; Sarah A Lewicki; Asmita Pramanik; Varun Gopinatth; Julie Pelletier; Jean Sévigny; Jamshed Iqbal; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2022-09-08       Impact factor: 2.940

3.  Extracellular ectonucleotidases are differentially regulated in murine tissues and human polymorphonuclear leukocytes during sepsis and inflammation.

Authors:  Clarissa B Haas; Marianna Lovászi; Pál Pacher; Priscila Oliveira de Souza; Julie Pelletier; Rafael Olive Leite; Jean Sévigny; Zoltán Németh; Elizandra Braganhol; György Haskó
Journal:  Purinergic Signal       Date:  2021-10-04       Impact factor: 3.765

4.  Neurotransmitters responsible for purinergic motor neurotransmission and regulation of GI motility.

Authors:  Kenton M Sanders; Violeta N Mutafova-Yambolieva
Journal:  Auton Neurosci       Date:  2021-06-02       Impact factor: 2.355

5.  Structure activity relationship of 3-nitro-2-(trifluoromethyl)-2H-chromene derivatives as P2Y6 receptor antagonists.

Authors:  Young-Hwan Jung; Shanu Jain; Varun Gopinatth; Ngan B Phung; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2021-04-06       Impact factor: 2.940

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.